NCT00528840 - Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

Advanced Dupuytren's Disease

Interventions

BIOLOGICAL

collagenase clostridium histolyticum

Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.

Trial Locations (14)

Hamot Center for Clinical Research, Erie

Alpha Clinical Research, Clarksville

David R. Mandel, Inc., Mayfield

The Indiana Hand Center, Indianapolis

St. Alexius Medical Center, Bismarck

Rockford Orthopedic Associates, Ltd., Rockford

Southern Illinois Hand Center, S.C., Effingham

Pri Via, Wichita

The Rheumatic Disease Clinic of Houston, Houston

Accurate Clincal Research, Houston

Hope Research Institute, Phoenix

Tucson Orthopedic Institute, P.C., Tucson

Providence Clinical Research, Burbank

St. Vincent Medical Center, Portland